Modified vaccinia ankara: Potential as an alternative smallpox vaccine

被引：72

作者：

McCurdy, LH ^{[1
]}

Larkin, BD ^{[1
]}

Martin, JE ^{[1
]}

Graham, BS ^{[1
]}

机构：

[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 38卷 / 12期

关键词：

D O I：

10.1086/421266

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. Although the currently available vaccine was used for the most successful medical intervention ever accomplished, it also is associated with side effects that are difficult to accept in a vaccine for a disease that has not been present for >25 years. Herein, we review alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses, and we suggest modified vaccinia Ankara (MVA) as a leading candidate for an alternative smallpox vaccine.

引用

页码：1749 / 1753

页数：5

共 47 条

[1]

ALCAMI A, 1995, J VIROL, V69, P4633

[2] The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses [J].